SRPT vs. RDY, UTHR, VTRS, BGNE, CTLT, TEVA, BMRN, ROIV, VKTX, and LEGN
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Viatris (VTRS), BeiGene (BGNE), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Roivant Sciences (ROIV), Viking Therapeutics (VKTX), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.
Sarepta Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
In the previous week, Sarepta Therapeutics had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Sarepta Therapeutics' average media sentiment score of 1.05 beat Dr. Reddy's Laboratories' score of 0.27 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
Sarepta Therapeutics currently has a consensus target price of $161.81, indicating a potential upside of 21.90%. Dr. Reddy's Laboratories has a consensus target price of $81.00, indicating a potential upside of 16.88%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Dr. Reddy's Laboratories.
Dr. Reddy's Laboratories has higher revenue and earnings than Sarepta Therapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 1108 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 59.25% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories has a net margin of 19.97% compared to Sarepta Therapeutics' net margin of 1.20%. Dr. Reddy's Laboratories' return on equity of 21.27% beat Sarepta Therapeutics' return on equity.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Sarepta Therapeutics beats Dr. Reddy's Laboratories on 12 of the 18 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
